La Jolla Pharmaceutical Company, incorporated on May 2, 1989, is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. On January 19, 2012, the Company acquired rights to certain assets, including a clinical-stage compound designated GCS-100, from Solana Therapeutics, Inc. (Solana). During the year ending December 31, 2012, the Company had not generated any revenues.The Company focuses on two product candidates: GCS-100 and LJPC-501. Its product, GCS-100, focuses on modulation of galectin-3, a member of the galectin family of proteins. Its second product candidate, LJPC-501,is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes.
公司网站: